Optimistic Phase III Leading Line Outcomes Demonstrate Efficacy of NER1006, a Novel
Norgine today announced positive top line final results for its phase III review, NOCT, a multicentre, randomised, parallel-group clinical trial comparing the bowel cleansing efficacy of a two-day split-dosing routine of NER1006, versus a split-dosing regimen …
Read through more on SYS-CON Media (press release)